GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Amneal Pharmaceuticals Inc (NAS:AMRX) » Definitions » 3-Year Revenue Growth Rate

AMRX (Amneal Pharmaceuticals) 3-Year Revenue Growth Rate : -13.10% (As of Mar. 2025)


View and export this data going back to 2018. Start your Free Trial

What is Amneal Pharmaceuticals 3-Year Revenue Growth Rate?

Amneal Pharmaceuticals's Revenue per Share for the three months ended in Mar. 2025 was $2.15.

During the past 12 months, Amneal Pharmaceuticals's average Revenue per Share Growth Rate was -27.70% per year. During the past 3 years, the average Revenue per Share Growth Rate was -13.10% per year. During the past 5 years, the average Revenue per Share Growth Rate was -4.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.

During the past 9 years, the highest 3-Year average Revenue per Share Growth Rate of Amneal Pharmaceuticals was 14.10% per year. The lowest was -13.10% per year. And the median was 3.90% per year.


Competitive Comparison of Amneal Pharmaceuticals's 3-Year Revenue Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Amneal Pharmaceuticals's 3-Year Revenue Growth Rate, along with its competitors' market caps and 3-Year Revenue Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Amneal Pharmaceuticals's 3-Year Revenue Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Amneal Pharmaceuticals's 3-Year Revenue Growth Rate distribution charts can be found below:

* The bar in red indicates where Amneal Pharmaceuticals's 3-Year Revenue Growth Rate falls into.


;
;

Amneal Pharmaceuticals 3-Year Revenue Growth Rate Calculation

This is the 3-year average growth rate of Revenue per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Revenue per Share growth rate.


Amneal Pharmaceuticals  (NAS:AMRX) 3-Year Revenue Growth Rate Explanation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top. Revenue per share growth rate is used in calculating Predictability Rank, companies with more consistent revenue and earnings growth are ranked high with predictability.


Amneal Pharmaceuticals 3-Year Revenue Growth Rate Related Terms

Thank you for viewing the detailed overview of Amneal Pharmaceuticals's 3-Year Revenue Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Amneal Pharmaceuticals Business Description

Traded in Other Exchanges
Address
400 Crossing Boulevard, 3rd Floor, Bridgewater, NJ, USA, 08807
Amneal Pharmaceuticals Inc is a pharmaceutical company operating in the U.S., India, and Ireland. With three reportable segments; Affordable Medicines, Specialty, and AvKARE - It develops, manufactures, and distributes a diverse portfolio of essential medicines. The Affordable Medicines segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Executives
Nikita Shah officer: SVP, Chief HR Officer C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807
John Kiely director C/O ZOVIO INC, 1811 E NORTHROP BLVD, CHANDLER AZ 85286
Gautam Patel director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BLVD, BRIDGEWATER NJ 08807
Tushar Bhikhubhai Patel 10 percent owner C/O TARSADIA INVESTMENTS, 520 NEWPORT CENTER DRIVE, 21ST FLOOR, NEWPORT BEACH CA 92660
Andrew S Boyer officer: Exec VP, Comm Optns C/O WATSON PHARMA INC, 360 MOUNT KEMBLE AVE, MORRISTOWN NJ 07960
Tasos Konidaris officer: SVP and CFO 103 JFK PARKWAY, SHORT HILLS NJ 07078
Deborah M. Autor director C/O PARDES BIOSCIENCES, INC., 2173 SALK AVE., SUITE 250, PMB#052, CARLSBAD CA 92008
Jason B. Daly officer: SVP, Chief Legal Officer 400 CROSSING BLVD, 3RD FLOOR, BRIDGEWATER NJ 08807
Tpg Gp A, Llc 10 percent owner 301 COMMERCE STREET, SUITE 3300, FORT WORTH TX 76102
Gustavo Pesquin officer: See Remarks 4 PARK LANE, MADISON NJ 07940
Jon Winkelried 10 percent owner C/O GOLDMAN, SACHS & CO., 85 BROAD STREET, NEW YORK NY 10004
Chirag K. Patel director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Chintu Patel director C/O AMNEAL PHARMACEUTICALS LLC, 400 CROSSING BOULEVARD, BRIDGEWATER CA 08807
Joseph Todisco officer: SVP, Specialty Commercial 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807
Jeffrey P. George director C/O AMNEAL PHARMACEUTICALS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807